Study of Aspirin in Patients With Vestibular Schwannoma


I'm Interested

Trial ID: NCT03079999


This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Official Title

Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas

Stanford Investigator(s)

Konstantina M. Stankovic, MD, PhD, FACS
Konstantina M. Stankovic, MD, PhD, FACS

Bertarelli Foundation Professor and Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery


Inclusion Criteria:

   - Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic).

   - Age≥12 years.

   - Ability to provide informed consent.Pediatric patients must provide assent in addition
   to their parents'/guardians' consent. Adult patients who cannot consent for themselves
   will not be eligible to participate in this study.

   - Ability to swallow tablets.

Exclusion Criteria:

   - Inability to perform volumetric measurements of vestibular schwannoma(s).

   - Inability to tolerate MRI with contrast.

   - Daily use of aspirin within the last two months. Occasional use of aspirin for pain
   relief is not exclusionary.

   - Known allergy to aspirin.

   - Impairment of gastrointestinal function or gastrointestinal disease that may
   significantly alter the absorption of aspirin.

   - Pregnant or lactating women.

   - Patients with serious medical illnesses (e.g. severe asthma) that in the option of the
   investigator could prevent participation in the trial.

   - Active bleeding diathesis.

   - Hydrocephalus from brainstem compression.

   - Febrile illness or flu-like illness in children and adolescents less than 18 years of


drug: Aspirin

drug: Placebo


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Homer Abaya